This post was originally published on this site
Truist’s downgrade of the stock over a year ago was rooted in concerns about the potential continuation of uneven trends experienced during the first half of 2022. These concerns were particularly tied to certain key categories that had witnessed remarkable growth during the pandemic, and were now grappling with what was described as a “post-pandemic hangover.”
Specifically, categories like vitamins and cat litter saw exceptional growth due to temporary shifts in consumer behavior during the pandemic.
“In fact, the vitamin business has struggled over the past year with a shrinking category and lost market share, however the cat litter business has remained strong,” the analysts said in a note.
The upgrade move comes after strong Q2 results and raised guidance.
“We view these results as a sign that the company and its categories are largely out of the woods from the post-pandemic reversion. Additionally, if key competitors, notably PG in detergent and CLX in litter, hold the line on pricing for the remainder of the year, as they have stated, we believe there is further upside to our margin and EPS estimates for CHD,” Truist analysts added.
Finally, they cited that CHD is back to its normal operating rhythm, which is seen as a major positive for the stock.
CHD shares are up 1% in early Monday premarket trade.
